Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.8K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.8K
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.6K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.6K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

189
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
189
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

209
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
209
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Foundations for the Successful Establishment of a Multidisciplinary Orthoplastic Surgery Team.

Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V...·2026
Same author

Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms.

Blood·2026
Same author

Association between vaccine-induced immune thrombocytopenia and thrombosis and human leucocyte antigen loci: Yes, no or maybe?

British journal of haematology·2026
Same author

Proteomic profiling identifies systemic drivers of blood-brain barrier injury in sickle cell disease.

Blood·2026
Same author

Vasospastic and Ischemic Disorders of the Upper Extremity: Vascular Radiology Collaborations Guiding Raynaud's Treatment Strategies.

Plastic and reconstructive surgery·2026
Same author

Introduction to a review series on hemophagocytic lymphohistiocytosis.

Blood·2026

Related Experiment Video

Updated: Dec 21, 2025

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.3K

ETV6-related thrombocytopenia and platelet dysfunction.

Jorge Di Paola1, Marlie H Fisher2,3

  • 1Department of Pediatrics, Washington University School of Medicine in St. Louis , St. Louis, Missouri, USA.

Platelets
|May 15, 2020
PubMed
Summary

Germline mutations in the ETV6 gene cause inherited thrombocytopenia, red cell macrocytosis, and leukemia predisposition. These ETV6 mutations also lead to impaired platelet function and bleeding issues.

Keywords:
BleedingETV6thrombocytopenia

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.4K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.0K

Related Experiment Videos

Last Updated: Dec 21, 2025

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
09:46

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

20.3K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.4K
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.0K

Area of Science:

  • Hematology
  • Genetics
  • Oncology

Background:

  • Germline heterozygote mutations in the ETV6 gene have been identified as a cause of autosomal dominant thrombocytopenia.
  • These mutations are associated with red cell macrocytosis and a predisposition to leukemia.
  • ETV6 mutations are found in 1% of acute lymphoblastic leukemia cases and 4.5% of inherited thrombocytopenia families.

Purpose of the Study:

  • To investigate the functional consequences of ETV6 germline mutations.
  • To understand the mechanisms underlying thrombocytopenia and platelet dysfunction in affected individuals.
  • To characterize the clinical presentation and prevalence of ETV6-related disorders.

Main Methods:

  • Analysis of patient data and family histories.
  • Bone marrow examination to assess megakaryocyte morphology and erythroid differentiation.
  • Preliminary functional studies on platelets from affected individuals.

Main Results:

  • ETV6 mutations lead to megakaryocyte maturation arrest and impaired platelet production.
  • Individuals with ETV6 mutations exhibit platelet dysfunction, including decreased spreading on fibrinogen.
  • Bleeding symptoms in affected individuals may be disproportionate to platelet count reduction.

Conclusions:

  • Germline ETV6 mutations represent a novel genetic cause of cancer predisposition, thrombocytopenia, and platelet dysfunction.
  • ETV6 mutations impact megakaryopoiesis and platelet function, contributing to a complex bleeding disorder.
  • Further research is warranted to fully elucidate the role of ETV6 in hematopoiesis and platelet biology.